Clinical Trials

1,301 enrolled 16 charts

Melanoma

NCT02954874 2026-04-13

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03030378 2026-04-13

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

36 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03244384 2026-04-13

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT03304639 2026-04-13

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

9 enrolled 11 charts

Carcinoma, Merkel Cell

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03854474 2026-04-13

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

30 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04164082 2026-04-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

161 enrolled

Urinary Bladder Neoplasms

NCT04214067 2026-04-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

164 enrolled

Sarcoma

Carcinosarcoma

NCT04214249 2026-04-13

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Other hematologic neoplasm

49 enrolled 32 charts

Leukemia, Myeloid, Acute

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

12 enrolled 25 charts

Thoracic

Lung Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

BreastGastrointestinalHead & NeckThoracic

329 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04284787 2026-04-13

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Other hematologic neoplasm

60 enrolled 11 charts

Leukemia, Myeloid, Acute

NCT04520711 2026-04-13

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

24 enrolled

Tumor-Agnostic

Carcinoma

NCT04548752 2026-04-13

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

88 enrolled

Pancreatic Neoplasms

NCT04708418 2026-04-13

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

60 enrolled

Melanoma

NCT05172258 2026-04-13

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

52 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05353439 2026-04-13

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

18 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07523763 2026-04-13

NIVO1002024

30 enrolled

Colorectal Neoplasms

NCT03277638 2026-04-09

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

32 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT04938609 2026-04-09

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

28 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04305054 2026-04-08

KEYMAKER-U02

315 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04847466 2026-04-08

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

18 enrolled

Tumor-Agnostic

Neoplasms

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

26 enrolled 9 charts

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

226 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05406713 2026-04-08

Pembrolizumab in Muscle-invasive Bladder Cancer

46 enrolled

Carcinoma, Transitional Cell

NCT06057038 2026-04-08

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

42 enrolled

Other solid neoplasm

Malignant Solid Tumor

NCT06099782 2026-04-08

MK-3475A-F11

DermatologicGenitourinaryThoracic

147 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06635824 2026-04-08

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

191 enrolled

Thoracic

Lung Neoplasms

NCT06984328 2026-04-08

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

1 enrolled

Melanoma, Recurrence

NCT03240211 2026-04-07

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

37 enrolled

Lymphoid

Lymphoma, T-Cell

NCT03485209 2026-04-07

innovaTV 207

GastrointestinalHead & NeckThoracic

352 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04417166 2026-04-07

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma